GlaxoSmithKline

In 2023, systemic sclerosis market size was USD 1,850M in 7MM, with the US leading. Italy had the largest market in EU4 and UK. The US also had the highest diagnosed cases. Treatments like OFEV and ACTEMRA are approved, but Rituximab showed significant improvements. Emerging therapies, including CAR-T cell therapies, are in development, promising future growth. The disease's severity varies by organ involvement, with lung disease being a major concern.

GSK raised its 2024 sales and earnings forecasts due to strong HIV and cancer drug performance, with Q2 sales up 13% to £7.88bn. Sales growth expected at 7%-9%, but vaccine sales outlook reduced. Core operating profit and EPS forecasts also increased.

The precision medicine market, valued at $73.11 billion in 2023, is projected to grow to $118.08 billion by 2028, driven by rising cancer prevalence and strategic collaborations. It segments by technology, application, and end-use, with major players including Roche, Pfizer, and Novartis.

CDC updated RSV vaccine recommendations, now advising shots for adults 75+ and high-risk individuals aged 60-74, diverging from last year's broader advice. The change, based on real-world data, aims to prioritize those at highest risk. This adjustment impacts vaccine makers GSK, Moderna, and Pfizer, narrowing their target market. Concerns over vaccine efficacy and a potential link to Guillain-Barré syndrome influenced the decision. Moderna's new RSV vaccine shows lower long-term efficacy compared to GSK and Pfizer's offerings.

GSK returns to China, partnering with DualityBio for a potential $1 billion deal, expanding its ADC portfolio after a previous $1.7 billion deal with Hansoh Pharma.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

AI is revolutionizing drug discovery, enabling faster identification of failures and novel drug targets. Companies like Recursion, Benevolent AI, and Lantern Pharma leverage AI for precision oncology and new molecule development, significantly reducing time and costs. Despite challenges, AI's potential to improve clinical trial success rates and efficiency is immense, with big pharma increasingly adopting AI technologies.

Switzerland excels in life sciences due to its strong regional hubs like Basel, Zurich, and Geneva/Lausanne, fostering innovation through bioparks and collaboration between academia and industry. This ecosystem supports start-ups and attracts global talent, maintaining Switzerland's leadership in drug discovery and biotech advancements.

The systemic sclerosis market is projected to grow significantly by 2034, driven by increasing prevalence, patient awareness, and novel therapies. Key companies like Kyowa Hakko Kirin and AstraZeneca are developing treatments such as Brodalumab and CABA-201, which have received regulatory designations. The market dynamics are influenced by emerging therapies, diagnostic improvements, and challenges like treatment eligibility and reimbursement.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.